NextCure, Inc.

US$5.33As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:NXTCHealthcare
Country USA
PE (Fwd) •••
TSR 7Y CAGR (39.47%)
Div yield —
ROE (204.56%)
Biotechnology
Beta (5Y) 1.20
PE TTM —
TSR TTM (57.70%)
Mkt cap US$24.40M
ROIC (93.24%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$6.63
24.33%
(91.93%)
Hold 3|6|8|6|8
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.05
0.05
0.05
0.06
9.93%
9.84%
11.97%
14.50%
Revenue$M
1.399
1.453
1.443
1.482
9.62%
7.90%
4.41%
8.06%
Peers (US$24.40M)
Cap (US$)
PE
24.67M
—
24.41M
—
Capital
TTM
5Y
10Y
Leveragex
1.237
(0.018)
(0.013)
EBIT/Intx
0.652
0.625
0.666
Own earn%
(6.13)
(18.97)
(19.97)
Sh yield%
29.19
24.14
23.84
Owners
Insiders/Inst%
6.34
46.13
Short interest%
3.74
SBC / revenue%
4.62
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
15
Op margin range%
10–16
$1 testx
—
Incr. ROIC%
−4